Compare VFC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | BLLN |
|---|---|---|
| Founded | 1899 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1994 | 2025 |
| Metric | VFC | BLLN |
|---|---|---|
| Price | $13.96 | $124.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 7 |
| Target Price | $18.24 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 6.2M | 523.3K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 103.40 |
| EPS | ★ 0.64 | 0.48 |
| Revenue | ★ $10,488,556,000.00 | $305,112,000.00 |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | $2.06 | $30.14 |
| P/E Ratio | ★ $21.41 | $260.21 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $12.46 | $61.96 |
| 52 Week High | $22.27 | $150.44 |
| Indicator | VFC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 69.01 |
| Support Level | $12.46 | $79.07 |
| Resistance Level | $15.32 | $150.44 |
| Average True Range (ATR) | 0.39 | 6.54 |
| MACD | 0.20 | 3.25 |
| Stochastic Oscillator | 96.75 | 92.38 |
VF designs, produces, and distributes apparel, footwear, and accessories with a focus on active and outdoor brands. Its portfolio of 10 labels includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and company-owned and partner-owned branded stores. Tracing its roots to 1899, VF has evolved into its present form through many brand acquisitions and divestitures.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.